Vyne Therapeutics Inc.
13F holders, Q4 2025 (December 31)2holders −1
0new positions
1sold out
$0.58avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Vyne Therapeutics Inc. in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were Staley Capital Advisers Inc. ($30K) and Farther Finance Advisors, LLC ($9).
- Company
- Vyne Therapeutics Inc.
- CUSIP
- 92941V209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $228 |
All 13F filers, Q3 2025 → Q4 2025: 680 shares sold, net −680 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Staley Capital Advisers Inc. | 0.00% | No change | 51,472 | $30K |
| Farther Finance Advisors, LLC | 0.00% | No change | 16 | $9 |
"% of holder's portfolio" is VYNE THERAPEUTICS INC's weight in each manager's 13F, not the share of Vyne Therapeutics Inc. the manager owns.